Sichuan Kelun Pharmaceutical Co Ltd (002422)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Sichuan Kelun Pharmaceutical Co Ltd (002422) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013342
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sichuan Kelun Pharmaceutical Co Ltd (Kelun) is a pharmaceutical company that manufactures and distributes IV Solutions. The company’s products include mannitol injection, glucose injection, sodium chloride injection, glucose and sodium chloride injection, ringer’s injection, lactated ringer’s injection, compound amino acid injection, alanyl glutamine injection, fructose injection, fructose and sodium chloride injection, compound amino acids, fat emulsion injection, vitamin c and glucose injection, vitamin c and sodium chloride injection, kang fu xin solution and lafutidine capsules. It also offers products to serve parenteral nutrition, digestive system, cardiovascular, antipsychotic, respiratory system, anti-pathogenic microorganisms, and APIs and intermediates. Kelun is headquartered in Chengdu, China.

Sichuan Kelun Pharmaceutical Co Ltd (002422) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Sichuan Kelun Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Debt Offering 11
Sichuan Kelun Pharma Raises USD210 Million in First Tranche of Public Offering of 5.38% Notes Due 2020 11
Sichuan Kelun Pharma Raises USD88.6 Million in Public Offering of 5.38% Bonds Due 2020 12
Sichuan Kelun Pharma Raises USD58 Million in Public Offering of 4.89% Bonds Due 2022 13
Sichuan Kelun Pharma Raises USD72.7 Million in Public Offering of Bonds 14
Sichuan Kelun Pharma Plans to Raise up to USD269.5 Million in Public Offering of Bonds 15
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2018 For US$175 Million 16
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2017 For US$238 Million 17
Sichuan Kelun Pharma Announces Debt Offering Of Notes Due 2017 For US$412 Million 18
Acquisition 19
Sichuan Kelun Pharma Plans to Acquire 35% stake in Changshu-Based Biotechnology Company 19
Sichuan Kelun Pharma Plans to Acquire Remaining 20% stake in Guangxi-Based Pharmaceutical Unit for USD5.3 Million 20
Sichuan Kelun Pharma Acquires KLUS Pharma for USD13 Million 21
Sichuan Kelun Pharma to Acquire 80% Stake in Biotechnology Company 22
Sichuan Kelun Pharma Plans to Acquire Remaining 15% Stake in Zhejiang-based pharmaceutical unit 23
Sichuan Kelun Pharma Acquires 56% Stake In Chengdu Pharma Company For US$32.8 Million 24
Sichuan Kelun Pharma Acquires Guizhou Kelun Pharma, Pharmaceutical Preparations Manufacturer 25
Sichuan Kelun Pharma Completes Acquisition of 80% Stake in Guilin Dahua Pharma for USD21.9 Million 26
Sichuan Kelun To Acquire 80% Stake In Gui Lin Dahua Pharma 27
Sichuan Kelun Pharmaceutical Co Ltd – Key Competitors 28
Sichuan Kelun Pharmaceutical Co Ltd – Key Employees 29
Sichuan Kelun Pharmaceutical Co Ltd – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sichuan Kelun Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Sichuan Kelun Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Sichuan Kelun Pharma Raises USD210 Million in First Tranche of Public Offering of 5.38% Notes Due 2020 11
Sichuan Kelun Pharma Raises USD88.6 Million in Public Offering of 5.38% Bonds Due 2020 12
Sichuan Kelun Pharma Raises USD58 Million in Public Offering of 4.89% Bonds Due 2022 13
Sichuan Kelun Pharma Raises USD72.7 Million in Public Offering of Bonds 14
Sichuan Kelun Pharma Plans to Raise up to USD269.5 Million in Public Offering of Bonds 15
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2018 For US$175 Million 16
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2017 For US$238 Million 17
Sichuan Kelun Pharma Announces Debt Offering Of Notes Due 2017 For US$412 Million 18
Sichuan Kelun Pharma Plans to Acquire 35% stake in Changshu-Based Biotechnology Company 19
Sichuan Kelun Pharma Plans to Acquire Remaining 20% stake in Guangxi-Based Pharmaceutical Unit for USD5.3 Million 20
Sichuan Kelun Pharma Acquires KLUS Pharma for USD13 Million 21
Sichuan Kelun Pharma to Acquire 80% Stake in Biotechnology Company 22
Sichuan Kelun Pharma Plans to Acquire Remaining 15% Stake in Zhejiang-based pharmaceutical unit 23
Sichuan Kelun Pharma Acquires 56% Stake In Chengdu Pharma Company For US$32.8 Million 24
Sichuan Kelun Pharma Acquires Guizhou Kelun Pharma, Pharmaceutical Preparations Manufacturer 25
Sichuan Kelun Pharma Completes Acquisition of 80% Stake in Guilin Dahua Pharma for USD21.9 Million 26
Sichuan Kelun To Acquire 80% Stake In Gui Lin Dahua Pharma 27
Sichuan Kelun Pharmaceutical Co Ltd, Key Competitors 28
Sichuan Kelun Pharmaceutical Co Ltd, Key Employees 29
Sichuan Kelun Pharmaceutical Co Ltd, Subsidiaries 30

★海外企業調査レポート[Sichuan Kelun Pharmaceutical Co Ltd (002422)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Pharma Holdings Inc (CPHI):企業の財務・戦略的SWOT分析
    China Pharma Holdings Inc (CPHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Abcam Plc (ABC)-医療機器分野:企業M&A・提携分析
    Summary Abcam Plc (Abcam) is a supplier of life science research tools for analysis of living cells at molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondar …
  • Synthetic Biologics Inc (SYN):企業の財務・戦略的SWOT分析
    Summary Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is …
  • Bellerophon Therapeutics Inc (BLPH):医療機器:M&Aディール及び事業提携情報
    Summary Bellerophon Therapeutics Inc (Bellerophon Therapeutics), formerly Bellerophon Therapeutics LLC is a clinical-stage biotherapeutics company that focuses on the development of therapies for the treatment of cardiopulmonary diseases. The company’s lead investigational cardiopulmonary product ca …
  • NOW Inc (DNOW):企業の財務・戦略的SWOT分析
    NOW Inc (DNOW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • BrainCool AB (BRAIN):企業の製品パイプライン分析2018
    Summary BrainCool AB (BrainCool), a subsidiary of Dignitana AB, is a medical device company that focuses on developing, and commercializing medical cooling systems for brain cooling and pain management. The company’s products are based on the principle that applying therapeutic hypothermia contribut …
  • Bank of the Ryukyus Ltd:企業の戦略・SWOT・財務分析
    Bank of the Ryukyus Ltd - Strategy, SWOT and Corporate Finance Report Summary Bank of the Ryukyus Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Agro Tech Foods Limited:企業の戦略・SWOT・財務情報
    Agro Tech Foods Limited - Strategy, SWOT and Corporate Finance Report Summary Agro Tech Foods Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Suncor Energy Inc (SU):電力:M&Aディール及び事業提携情報
    Summary Suncor Energy Inc. (Suncor) is an integrated energy company that mainly focuses on the development of Athabasca oil sands. It carries out development and up gradation of oil sands; offshore and onshore oil and gas production; refining of crude oil and marketing of petroleum and petrochemical …
  • Verso Corporation:企業の戦略・SWOT・財務情報
    Verso Corporation - Strategy, SWOT and Corporate Finance Report Summary Verso Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Woolworths Limited:企業の戦略・SWOT・財務情報
    Woolworths Limited - Strategy, SWOT and Corporate Finance Report Summary Woolworths Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Nu Skin Enterprises, Inc.:企業の戦略・SWOT・財務情報
    Nu Skin Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nu Skin Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Sierra Oncology Inc (SRRA):製薬・医療:M&Aディール及び事業提携情報
    Summary Sierra Oncology Inc (Sierra Oncology), formerly ProNAi Therapeutics Inc is a clinical stage drug development company that develops and commercializes DNA damage response therapeutics for the treatment of cancer. The company’s product candidate includes SRA737, an orally bioavailable small mo …
  • Klox Technologies Inc-製薬・医療分野:企業M&A・提携分析
    Summary Klox Technologies Inc (Klox Technologies) is a specialty pharmaceutical company, which focuses on the development and commercialization of a proprietary BioPhotonic technology platform. Its pipeline portfolio includes non-invasive wound care treatment solutions, dermatological treatment solu …
  • numares AG:企業の製品パイプライン分析2018
    Summary Numares AG (Numares), formerly Numares GmbH, is a developer and marketer of products for life science research and clinical diagnostics. The company’s AXINON lipoFIT, a test system used for lipoprotein profiling, while insightLP provides insights into lipid related research using lipoprotein …
  • Bank of America Corporation:企業のM&A・事業提携・投資動向
    Bank of America Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of America Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • R1 RCM Inc (RCM):企業の財務・戦略的SWOT分析
    R1 RCM Inc (RCM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Reckitt Benckiser Group Plc (RB.):企業の財務・戦略的SWOT分析
    Reckitt Benckiser Group Plc (RB.) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Witte Molen NV:企業の戦略・SWOT・財務分析
    Witte Molen NV - Strategy, SWOT and Corporate Finance Report Summary Witte Molen NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Octapharma AG:企業の戦略・SWOT・財務分析
    Octapharma AG - Strategy, SWOT and Corporate Finance Report Summary Octapharma AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆